CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours
Cells · 2023
DOI: 10.3390/cells12121586 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Hiu Kwan Carolyn Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neuroblastoma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Although exponential progress in treating advanced malignancy has been made in the modern era with immune checkpoint blockade, survival outcomes remain suboptimal. Cellular immunotherapy, such as chimeric antigen receptor T cells, has the potential to improve this. CAR T cells combine the antigen specificity of a monoclonal antibody with the cytotoxic ‘power’ of T-lymphocytes through expression of a transgene encoding the scFv domain, CD3 activation molecule, and co-stimulatory domains. Although, very rarely, fatal cytokine-release syndrome may occur, CAR T-cell therapy gives patients with refractory CD19-positive B-lymphoid malignancies an important further therapeutic option. However, low-level expression of epithelial tumour-associated-antigens on non-malignant cells makes the application of CAR T-cell technology to common solid cancers challenging, as does the potentially limited ability of CAR T cells to traffic outside the blood/lymphoid microenvironment into metastatic lesions. Despite this, in advanced neuroblastoma refractory to standard therapy, 60% long-term overall survival and an objective response in 63% was achieved with anti GD2-specific CAR T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
- University of Cambridge, Trinity Hall, Cambridge CB3 9DP, UK.
ORCID-Profile: Hui Xian Tan
Zitieren
APA
Tang, H. K. C., Wang, B., Tan, H. X., Sarwar, M. A., Baraka, B., Shafiq, T., & Rao, A. R. (2023). CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours. Cells. https://doi.org/10.3390/cells12121586
Vancouver
Tang HKC, Wang B, Tan HX, Sarwar MA, Baraka B, Shafiq T, et al. CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours. Cells. 2023. doi:10.3390/cells12121586
BibTeX
@article{Tang2023,
author = {Tang, Hiu Kwan Carolyn and Wang, Bo and Tan, Hui Xian and Sarwar, Muhammad Adeel and Baraka, Bahaaeldin and Shafiq, Tahir and Rao, Ankit R},
title = {CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12121586}
}
EUVIMED